L & L Bio Co., Ltd., Ningbo, China
Clinical trials sponsored by L & L Bio Co., Ltd., Ningbo, China, explained in plain language.
-
Experimental combo aims to fight Hard-to-Treat cancers
Disease control Recruiting nowThis study tests two experimental drugs, LB1410 and LB4330, given together to people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to find safe doses and to see if the combination can shrink tumors or slow their growth…
Phase: PHASE1, PHASE2 • Sponsor: L & L Bio Co., Ltd., Ningbo, China • Aim: Disease control
Last updated Jun 26, 2026 16:03 UTC
-
New Dual-Target antibody enters human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called LB1410, a bispecific antibody designed to block two immune checkpoints (PD-1 and TIM-3) and help the immune system fight cancer. It involves 100 adults with advanced solid tumors or lymphoma who have exhausted standard…
Phase: PHASE1 • Sponsor: L & L Bio Co., Ltd., Ningbo, China • Aim: Disease control
Last updated Jun 26, 2026 15:48 UTC